25 XP   0   0   10

Vyne Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Vyne Therapeutics Inc together

PenkeI guess you are interested in Vyne Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Vyne Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Vyne Therapeutics Inc

I send you an email if I find something interesting about Vyne Therapeutics Inc.

Quick analysis of Vyne Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Vyne Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$6.29
Expected worth in 1 year
$10.37
How sure are you?
20.7%

+ What do you gain per year?

Total Gains per Share
$4.08
Return On Investment
177.4%

For what price can you sell your share?

Current Price per Share
$2.30
Expected price per share
$1.67 - $4.293
How sure are you?
50%

1. Valuation of Vyne Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$2.30

Intrinsic Value Per Share

$47.49 - $58.38

Total Value Per Share

$53.79 - $64.67

2. Growth of Vyne Therapeutics Inc (5 min.)




Is Vyne Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$88.7m$43.8m-$7.8m-21.8%

How much money is Vyne Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$7.1m-$5.2m-$1.8m-26.1%
Net Profit Margin-6,761.7%-34,779.4%--

How much money comes from the company's main activities?

3. Financial Health of Vyne Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#395 / 1016

Most Revenue
#631 / 1016

Most Profit
#486 / 1016

Most Efficient
#930 / 1016

What can you expect buying and holding a share of Vyne Therapeutics Inc? (5 min.)

Welcome investor! Vyne Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Vyne Therapeutics Inc.

What can you expect buying and holding a share of Vyne Therapeutics Inc?

First you should know what it really means to hold a share of Vyne Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Vyne Therapeutics Inc is $2.3. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Vyne Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Vyne Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.29. Based on the TTM, the Book Value Change Per Share is $1.02 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.31 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Vyne Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.44-19.1%-0.58-25.4%-0.41-17.9%-1.71-74.2%-1.39-60.3%
Usd Book Value Change Per Share5.48238.2%1.0244.4%-0.31-13.4%-0.15-6.4%0.229.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share5.48238.2%1.0244.4%-0.31-13.4%-0.15-6.4%0.229.4%
Usd Price Per Share2.33-3.39-0.35-2.92-4.07-
Price to Earnings Ratio-1.33--1.50-0.05--0.64--1.04-
Price-to-Total Gains Ratio0.43--6.22--0.02--0.20--1.36-
Price to Book Ratio0.37-2.58-0.11-0.92-0.82-
Price-to-Total Gains Ratio0.43--6.22--0.02--0.20--1.36-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.3
Number of shares434
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share1.02-0.15
Usd Total Gains Per Share1.02-0.15
Gains per Quarter (434 shares)442.75-64.09
Gains per Year (434 shares)1,771.01-256.37
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10177117610-256-266
20354235320-513-522
30531353030-769-778
40708470740-1025-1034
50885588450-1282-1290
6010626106160-1538-1546
7012397123870-1795-1802
8014168141580-2051-2058
9015939159290-2307-2314
10017710177000-2564-2570

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.028.00.03.4%1.028.00.03.4%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%6.021.02.020.7%6.021.02.020.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.029.00.0%0.00.029.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%6.021.02.020.7%6.021.02.020.7%

Fundamentals of Vyne Therapeutics Inc

About Vyne Therapeutics Inc

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Fundamental data was last updated by Penke on 2024-04-12 21:58:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Vyne Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Vyne Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Vyne Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -8,142.1% means that $-81.42 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vyne Therapeutics Inc:

  • The MRQ is -8,142.1%. The company is making a huge loss. -2
  • The TTM is -6,761.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-8,142.1%TTM-6,761.7%-1,380.4%
TTM-6,761.7%YOY-34,779.4%+28,017.7%
TTM-6,761.7%5Y-8,659.3%+1,897.6%
5Y-8,659.3%10Y-6,225.7%-2,433.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8,142.1%-199.6%-7,942.5%
TTM-6,761.7%-213.0%-6,548.7%
YOY-34,779.4%-279.3%-34,500.1%
5Y-8,659.3%-438.4%-8,220.9%
10Y-6,225.7%-605.5%-5,620.2%
1.1.2. Return on Assets

Shows how efficient Vyne Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Vyne Therapeutics Inc to the Biotechnology industry mean.
  • -6.3% Return on Assets means that Vyne Therapeutics Inc generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vyne Therapeutics Inc:

  • The MRQ is -6.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -24.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.3%TTM-24.2%+17.9%
TTM-24.2%YOY-11.8%-12.4%
TTM-24.2%5Y-24.5%+0.4%
5Y-24.5%10Y-20.3%-4.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.3%-13.5%+7.2%
TTM-24.2%-12.9%-11.3%
YOY-11.8%-11.8%0.0%
5Y-24.5%-14.1%-10.4%
10Y-20.3%-16.0%-4.3%
1.1.3. Return on Equity

Shows how efficient Vyne Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Vyne Therapeutics Inc to the Biotechnology industry mean.
  • -7.0% Return on Equity means Vyne Therapeutics Inc generated $-0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vyne Therapeutics Inc:

  • The MRQ is -7.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -35.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.0%TTM-35.9%+29.0%
TTM-35.9%YOY-14.4%-21.5%
TTM-35.9%5Y-39.8%+3.9%
5Y-39.8%10Y-28.7%-11.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.0%-16.9%+9.9%
TTM-35.9%-16.1%-19.8%
YOY-14.4%-15.1%+0.7%
5Y-39.8%-19.9%-19.9%
10Y-28.7%-20.9%-7.8%

1.2. Operating Efficiency of Vyne Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Vyne Therapeutics Inc is operating .

  • Measures how much profit Vyne Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Vyne Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vyne Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,910.7%+1,910.7%
TTM-1,910.7%YOY-37,528.7%+35,618.0%
TTM-1,910.7%5Y-8,167.1%+6,256.4%
5Y-8,167.1%10Y-5,893.0%-2,274.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--295.1%+295.1%
TTM-1,910.7%-225.8%-1,684.9%
YOY-37,528.7%-288.4%-37,240.3%
5Y-8,167.1%-477.4%-7,689.7%
10Y-5,893.0%-625.6%-5,267.4%
1.2.2. Operating Ratio

Measures how efficient Vyne Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 90.89 means that the operating costs are $90.89 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Vyne Therapeutics Inc:

  • The MRQ is 90.895. The company is inefficient in keeping operating costs low. -1
  • The TTM is 71.088. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ90.895TTM71.088+19.807
TTM71.088YOY376.567-305.479
TTM71.0885Y92.743-21.655
5Y92.74310Y66.807+25.936
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ90.8953.090+87.805
TTM71.0883.264+67.824
YOY376.5673.783+372.784
5Y92.7435.679+87.064
10Y66.8077.894+58.913

1.3. Liquidity of Vyne Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Vyne Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 12.73 means the company has $12.73 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Vyne Therapeutics Inc:

  • The MRQ is 12.731. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.860. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ12.731TTM5.860+6.871
TTM5.860YOY6.299-0.439
TTM5.8605Y5.902-0.042
5Y5.90210Y7.430-1.528
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.7313.914+8.817
TTM5.8604.220+1.640
YOY6.2995.388+0.911
5Y5.9026.045-0.143
10Y7.4306.406+1.024
1.3.2. Quick Ratio

Measures if Vyne Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Vyne Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 20.69 means the company can pay off $20.69 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vyne Therapeutics Inc:

  • The MRQ is 20.687. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.607. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ20.687TTM7.607+13.080
TTM7.607YOY5.854+1.753
TTM7.6075Y6.949+0.658
5Y6.94910Y10.127-3.178
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.6873.572+17.115
TTM7.6073.998+3.609
YOY5.8545.390+0.464
5Y6.9495.969+0.980
10Y10.1276.287+3.840

1.4. Solvency of Vyne Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Vyne Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Vyne Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.09 means that Vyne Therapeutics Inc assets are financed with 9.2% credit (debt) and the remaining percentage (100% - 9.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Vyne Therapeutics Inc:

  • The MRQ is 0.092. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.263. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.092TTM0.263-0.172
TTM0.263YOY0.159+0.104
TTM0.2635Y0.282-0.019
5Y0.28210Y0.499-0.217
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0920.336-0.244
TTM0.2630.334-0.071
YOY0.1590.269-0.110
5Y0.2820.366-0.084
10Y0.4990.390+0.109
1.4.2. Debt to Equity Ratio

Measures if Vyne Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Vyne Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 10.1% means that company has $0.10 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vyne Therapeutics Inc:

  • The MRQ is 0.101. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.389. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.101TTM0.389-0.288
TTM0.389YOY0.193+0.196
TTM0.3895Y0.489-0.100
5Y0.48910Y0.346+0.142
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1010.382-0.281
TTM0.3890.396-0.007
YOY0.1930.335-0.142
5Y0.4890.434+0.055
10Y0.3460.465-0.119

2. Market Valuation of Vyne Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Vyne Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Vyne Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -1.33 means the investor is paying $-1.33 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vyne Therapeutics Inc:

  • The EOD is -1.310. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.327. Based on the earnings, the company is expensive. -2
  • The TTM is -1.502. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.310MRQ-1.327+0.017
MRQ-1.327TTM-1.502+0.174
TTM-1.502YOY0.048-1.550
TTM-1.5025Y-0.638-0.864
5Y-0.63810Y-1.041+0.403
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.310-2.259+0.949
MRQ-1.327-2.569+1.242
TTM-1.502-2.664+1.162
YOY0.048-4.120+4.168
5Y-0.638-6.258+5.620
10Y-1.041-6.171+5.130
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Vyne Therapeutics Inc:

  • The EOD is -1.578. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.599. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.963. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.578MRQ-1.599+0.021
MRQ-1.599TTM-1.963+0.365
TTM-1.963YOY-0.161-1.803
TTM-1.9635Y-0.880-1.083
5Y-0.88010Y-1.218+0.338
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.578-2.924+1.346
MRQ-1.599-3.246+1.647
TTM-1.963-3.488+1.525
YOY-0.161-5.620+5.459
5Y-0.880-8.315+7.435
10Y-1.218-8.826+7.608
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Vyne Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.37 means the investor is paying $0.37 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Vyne Therapeutics Inc:

  • The EOD is 0.365. Based on the equity, the company is cheap. +2
  • The MRQ is 0.370. Based on the equity, the company is cheap. +2
  • The TTM is 2.578. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.365MRQ0.370-0.005
MRQ0.370TTM2.578-2.207
TTM2.578YOY0.106+2.472
TTM2.5785Y0.924+1.654
5Y0.92410Y0.820+0.104
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.3651.851-1.486
MRQ0.3702.090-1.720
TTM2.5782.095+0.483
YOY0.1062.844-2.738
5Y0.9243.466-2.542
10Y0.8203.815-2.995
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Vyne Therapeutics Inc.

3.1. Institutions holding Vyne Therapeutics Inc

Institutions are holding 60.798% of the shares of Vyne Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Eventide Asset Management, LLC9.88970.053139433613943360
2023-12-31Cormorant Asset Management, LLC9.88970.1552139433613943360
2023-12-31Soleus Capital Management, L.P.4.99240.1827038687038680
2023-12-31Parkman Healthcare Partners LLC4.93990.22866964706964700
2023-12-31AlphaCentric Advisors, LLC4.7391.0456681516681510
2023-12-31Palo Alto Investors, LLC3.15940.09354454344454340
2023-12-31Exome Asset Management LLC0.83770.27211181001181000
2023-12-31Springbok Capital Management, LLC0.83770.01821181001181000
2023-09-30Dsc Advisors LP0.81570.590511500000
2023-12-31Geode Capital Management, LLC0.669209434366809242.6418
2023-12-31Susquehanna International Group, LLP0.4279060323-15448-20.3877
2023-12-31Fred Alger Management, LLC0.4260.000860055600550
2023-12-31Vanguard Group Inc0.3517049582468710.4399
2023-12-31BlackRock Inc0.335504729723585.2471
2023-12-31Renaissance Technologies Corp0.32890.0002463762040078.534
2023-12-31Northern Trust Corp0.2621036951369510
2023-12-31Millennium Management LLC0.1225017273172730
2023-12-31State Street Corporation0.082701166500
2023-12-31HRT FINANCIAL LLC0.07120.000210043100430
2023-12-31U.S. Bancorp0.03150444400
Total 43.21042.63936092147+5741923+94.3%

3.2. Funds holding Vyne Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31AlphaCentric LifeSci Healthcare I4.7391.49356681516681510
2024-02-29Fidelity Extended Market Index0.5550.000578247-379-0.482
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.44520.0001627651268725.3345
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.16090.00082268720043758.056
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.12920.00081822116101759.4811
2023-12-31Northern Trust Extended Eq Market Idx0.09090.00051281510818541.7126
2023-12-31NT Ext Equity Mkt Idx Fd - L0.09090.00051281510818541.7126
2024-02-29Fidelity Total Market Index0.089401260600
2024-02-29Vifag 2002 SICAV0.07370.03621038400
2024-02-29Fidelity Series Total Market Index0.0680958100
2023-09-30BlackRock Extended Mkt Composite0.04250.0002598600
2024-03-31BlackRock Extended Equity Market K0.03710.0001522420.0383
2023-12-31Franklin U.S. Small Cap Equity I0.03690.0127519600
2024-02-29Fidelity Nasdaq Composite Index0.02980.0001419900
2024-02-29Spartan Extended Market Index Pool E0.00830.0001117737947.4937
2024-02-29Vanguard U.S. Eq Idx £ Acc0.00710100400
2024-03-31State St US Extended Mkt Indx NL Cl C0.00690.000297400
2023-12-31SSgA U.S. Extended Market Index Class I0.00690.000197400
2024-02-29Spartan Total Market Index Pool E0.0067094300
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.00520.0008734648753.4884
Total 6.62961.5472934683+739268+79.1%

3.3. Insider Transactions

Insiders are holding 8.696% of the shares of Vyne Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-15Patrick G LeporeBUY130003.91

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Vyne Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--5.4781.020+437%-0.309+106%-0.148+103%0.217+2424%
Book Value Per Share--6.2942.552+147%3.109+102%4.241+48%3.923+60%
Current Ratio--12.7315.860+117%6.299+102%5.902+116%7.430+71%
Debt To Asset Ratio--0.0920.263-65%0.159-43%0.282-68%0.499-82%
Debt To Equity Ratio--0.1010.389-74%0.193-48%0.489-79%0.346-71%
Dividend Per Share----0%-0%-0%-0%
Eps---0.439-0.583+33%-0.412-6%-1.707+289%-1.386+216%
Free Cash Flow Per Share---0.364-0.449+23%-0.518+42%-1.111+205%-0.976+168%
Free Cash Flow To Equity Per Share--5.4991.012+444%-0.488+109%-0.435+108%-0.080+101%
Gross Profit Margin--2.5341.383+83%1.000+153%1.077+135%1.053+141%
Intrinsic Value_10Y_max--58.381--------
Intrinsic Value_10Y_min--47.495--------
Intrinsic Value_1Y_max---1.398--------
Intrinsic Value_1Y_min---1.377--------
Intrinsic Value_3Y_max--1.324--------
Intrinsic Value_3Y_min--1.153--------
Intrinsic Value_5Y_max--10.705--------
Intrinsic Value_5Y_min--9.461--------
Market Cap32427470.000-1%32850437.00047760023.750-31%4976911.700+560%41124376.465-20%57371341.114-43%
Net Profit Margin---81.421-67.617-17%-347.794+327%-86.593+6%-62.257-24%
Operating Margin----19.1070%-375.2870%-81.6710%-58.9300%
Operating Ratio--90.89571.088+28%376.567-76%92.743-2%66.807+36%
Pb Ratio0.365-1%0.3702.578-86%0.106+249%0.924-60%0.820-55%
Pe Ratio-1.310+1%-1.327-1.502+13%0.048-2857%-0.638-52%-1.041-22%
Price Per Share2.300-1%2.3303.388-31%0.353+560%2.917-20%4.069-43%
Price To Free Cash Flow Ratio-1.578+1%-1.599-1.963+23%-0.161-90%-0.880-45%-1.218-24%
Price To Total Gains Ratio0.420-1%0.425-6.216+1561%-0.017+104%-0.197+146%-1.358+419%
Quick Ratio--20.6877.607+172%5.854+253%6.949+198%10.127+104%
Return On Assets---0.063-0.242+282%-0.118+87%-0.245+287%-0.203+220%
Return On Equity---0.070-0.359+415%-0.144+107%-0.398+471%-0.287+311%
Total Gains Per Share--5.4781.020+437%-0.309+106%-0.148+103%0.217+2424%
Usd Book Value--88735000.00035985750.000+147%43839750.000+102%59800400.000+48%55304896.552+60%
Usd Book Value Change Per Share--5.4781.020+437%-0.309+106%-0.148+103%0.217+2424%
Usd Book Value Per Share--6.2942.552+147%3.109+102%4.241+48%3.923+60%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.439-0.583+33%-0.412-6%-1.707+289%-1.386+216%
Usd Free Cash Flow---5137000.000-6335250.000+23%-7300000.000+42%-15666450.000+205%-13755137.931+168%
Usd Free Cash Flow Per Share---0.364-0.449+23%-0.518+42%-1.111+205%-0.976+168%
Usd Free Cash Flow To Equity Per Share--5.4991.012+444%-0.488+109%-0.435+108%-0.080+101%
Usd Market Cap32427470.000-1%32850437.00047760023.750-31%4976911.700+560%41124376.465-20%57371341.114-43%
Usd Price Per Share2.300-1%2.3303.388-31%0.353+560%2.917-20%4.069-43%
Usd Profit---6188000.000-7113000.000+15%-5256500.000-15%-22603900.000+265%-18532275.862+199%
Usd Revenue--76000.000106000.000-28%119250.000-36%1832450.000-96%1437275.862-95%
Usd Total Gains Per Share--5.4781.020+437%-0.309+106%-0.148+103%0.217+2424%
 EOD+2 -6MRQTTM+25 -8YOY+27 -65Y+29 -410Y+27 -6

4.2. Fundamental Score

Let's check the fundamental score of Vyne Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.310
Price to Book Ratio (EOD)Between0-10.365
Net Profit Margin (MRQ)Greater than0-81.421
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than120.687
Current Ratio (MRQ)Greater than112.731
Debt to Asset Ratio (MRQ)Less than10.092
Debt to Equity Ratio (MRQ)Less than10.101
Return on Equity (MRQ)Greater than0.15-0.070
Return on Assets (MRQ)Greater than0.05-0.063
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Vyne Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.916
Ma 20Greater thanMa 502.730
Ma 50Greater thanMa 1002.399
Ma 100Greater thanMa 2002.450
OpenGreater thanClose2.390
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets97,685
Total Liabilities8,950
Total Stockholder Equity88,735
 As reported
Total Liabilities 8,950
Total Stockholder Equity+ 88,735
Total Assets = 97,685

Assets

Total Assets97,685
Total Current Assets95,963
Long-term Assets1,722
Total Current Assets
Cash And Cash Equivalents 30,674
Short-term Investments 62,633
Other Current Assets 2,656
Total Current Assets  (as reported)95,963
Total Current Assets  (calculated)95,963
+/-0
Long-term Assets
Property Plant Equipment 207
Long-term Assets Other 1,515
Long-term Assets  (as reported)1,722
Long-term Assets  (calculated)1,722
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities7,538
Long-term Liabilities1,412
Total Stockholder Equity88,735
Total Current Liabilities
Short-term Debt 115
Accounts payable 1,659
Other Current Liabilities 5,764
Total Current Liabilities  (as reported)7,538
Total Current Liabilities  (calculated)7,538
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt99
Long-term Liabilities Other 1,313
Long-term Liabilities  (as reported)1,412
Long-term Liabilities  (calculated)1,412
+/- 0
Total Stockholder Equity
Common Stock1
Retained Earnings -691,336
Accumulated Other Comprehensive Income 26
Other Stockholders Equity 780,044
Total Stockholder Equity (as reported)88,735
Total Stockholder Equity (calculated)88,735
+/-0
Other
Capital Stock1
Cash and Short Term Investments 93,307
Common Stock Shares Outstanding 3,105
Liabilities and Stockholders Equity 97,685
Net Debt -30,460
Net Invested Capital 88,735
Net Working Capital 88,425
Property Plant and Equipment Gross 207
Short Long Term Debt Total 214



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
42,053
0
0
75,800
66,867
180,479
166,916
154,958
139,928
126,258
114,384
96,576
79,169
160,533
130,842
107,683
93,742
149,171
133,983
81,315
67,046
64,319
55,192
46,908
40,758
35,263
24,959
19,267
97,685
97,68519,26724,95935,26340,75846,90855,19264,31967,04681,315133,983149,17193,742107,683130,842160,53379,16996,576114,384126,258139,928154,958166,916180,47966,86775,8000042,053
   > Total Current Assets 
31,540
0
0
75,782
63,861
159,658
156,163
154,468
139,500
125,222
113,127
93,429
78,327
98,441
119,290
98,162
87,259
143,117
128,426
76,129
63,186
60,654
51,920
44,046
38,275
33,022
22,959
17,511
95,963
95,96317,51122,95933,02238,27544,04651,92060,65463,18676,129128,426143,11787,25998,162119,29098,44178,32793,429113,127125,222139,500154,468156,163159,65863,86175,7820031,540
       Cash And Cash Equivalents 
4,027
0
0
14,958
10,206
78,527
73,584
70,196
49,510
61,958
65,055
34,244
30,777
57,601
96,511
72,956
57,563
118,516
103,406
52,306
42,250
50,495
42,814
35,510
30,908
30,213
20,634
15,448
30,674
30,67415,44820,63430,21330,90835,51042,81450,49542,25052,306103,406118,51657,56372,95696,51157,60130,77734,24465,05561,95849,51070,19673,58478,52710,20614,958004,027
       Short-term Investments 
26,881
0
0
58,589
49,295
77,310
80,171
82,461
86,740
59,558
44,355
57,112
46,167
23,790
2,609
3,046
1,027
1,027
1,027
0
0
0
0
0
0
0
0
0
62,633
62,6330000000001,0271,0271,0273,0462,60923,79046,16757,11244,35559,55886,74082,46180,17177,31049,29558,5890026,881
       Net Receivables 
0
0
0
460
786
234
93
0
0
0
0
979
135
8,333
10,407
11,189
15,819
10,755
10,868
10,084
7,583
5,535
5,304
5,471
5,173
105
234
250
0
02502341055,1735,4715,3045,5357,58310,08410,86810,75515,81911,18910,4078,333135979000093234786460000
       Other Current Assets 
632
0
0
1,775
3,574
3,587
2,315
1,811
3,250
3,706
3,717
2,073
1,383
4,236
3,962
4,321
5,446
4,727
5,873
5,669
338
124
30
3,065
2,097
2,704
2,024
1,759
2,656
2,6561,7592,0242,7042,0973,065301243385,6695,8734,7275,4464,3213,9624,2361,3832,0733,7173,7063,2501,8112,3153,5873,5741,77500632
   > Long-term Assets 
10,513
0
0
18
3,006
20,821
10,753
490
428
1,036
1,257
3,147
842
62,092
11,552
9,521
6,483
6,054
5,557
5,186
3,860
3,665
3,272
2,862
2,483
2,241
2,000
1,756
1,722
1,7221,7562,0002,2412,4832,8623,2723,6653,8605,1865,5576,0546,4839,52111,55262,0928423,1471,2571,03642849010,75320,8213,006180010,513
       Property Plant Equipment 
27
0
0
18
28
25
22
136
146
813
1,113
943
769
4,555
5,369
4,935
2,138
1,936
1,726
1,508
354
310
298
127
282
0
0
0
207
2070002821272983103541,5081,7261,9362,1384,9355,3694,5557699431,113813146136222528180027
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
4,045
0
0
4,545
4,545
4,545
0
0
0
0
0
0
0
0
0
0
00000000004,5454,5454,545004,0450000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
2,004
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000002,00400000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
50,300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000050,3000000000000000
       Long-term Assets Other 
66
0
0
0
0
83
306
354
282
223
144
200
73
3,192
6,183
4,586
-200
4,118
3,831
3,678
3,506
3,355
2,974
2,735
2,201
2,241
2,000
1,756
1,515
1,5151,7562,0002,2412,2012,7352,9743,3553,5063,6783,8314,118-2004,5866,1833,1927320014422328235430683000066
> Total Liabilities 
71,494
0
0
123,761
123,901
14,777
8,727
8,074
9,551
10,627
12,207
9,574
10,661
90,998
59,314
58,167
56,249
56,270
59,090
22,429
18,410
8,588
6,835
6,839
9,556
8,832
7,687
7,762
8,950
8,9507,7627,6878,8329,5566,8396,8358,58818,41022,42959,09056,27056,24958,16759,31490,99810,6619,57412,20710,6279,5518,0748,72714,777123,901123,7610071,494
   > Total Current Liabilities 
3,903
0
0
7,222
7,817
8,471
8,649
8,062
9,544
10,627
11,906
9,452
10,661
56,586
24,232
23,192
21,453
21,549
57,620
20,997
18,410
8,588
6,835
6,839
9,345
7,519
6,374
6,449
7,538
7,5386,4496,3747,5199,3456,8396,8358,58818,41020,99757,62021,54921,45323,19224,23256,58610,6619,45211,90610,6279,5448,0628,6498,4717,8177,222003,903
       Short-term Debt 
518
0
0
1,649
3,358
2,976
0
0
0
684
715
741
700
1,009
1,245
1,098
757
647
33,809
277
349
117
31
0
0
0
0
0
115
115000003111734927733,8096477571,0981,2451,0097007417156840002,9763,3581,64900518
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,375
0
0
0
0
0
0
0
0
0
0
000000000033,375000000000000000000
       Accounts payable 
1,526
0
0
3,527
2,462
3,501
5,089
2,702
3,290
3,782
4,704
2,992
3,771
14,114
9,952
4,622
4,780
3,490
10,080
7,621
6,510
3,612
1,431
2,523
2,386
2,214
1,159
716
1,659
1,6597161,1592,2142,3862,5231,4313,6126,5107,62110,0803,4904,7804,6229,95214,1143,7712,9924,7043,7823,2902,7025,0893,5012,4623,527001,526
       Other Current Liabilities 
63
0
0
250
201
198
3,560
5,360
6,254
424
506
395
485
21,208
142
46
104
104
104
104
11,551
4,859
2,399
4,316
6,959
5,305
5,215
5,733
5,764
5,7645,7335,2155,3056,9594,3162,3994,85911,5511041041041044614221,2084853955064246,2545,3603,5601982012500063
   > Long-term Liabilities 
67,591
0
0
116,539
116,084
6,306
78
12
7
0
301
122
0
34,412
35,082
34,975
34,796
34,721
1,470
1,432
6,859
3,729
2,399
-349
211
1,313
1,313
1,313
1,412
1,4121,3131,3131,313211-3492,3993,7296,8591,4321,47034,72134,79634,97535,08234,41201223010712786,306116,084116,5390067,591
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
875
880
867
859
866
769
663
658
657
0
0
0
0
0
0
1,313
0
0
001,31300000065765866376986685986788087500000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
50,300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000050,3000000000000000
> Total Stockholder Equity
-29,441
0
0
-47,961
-57,034
165,702
158,189
146,884
130,377
115,631
102,177
87,002
68,508
69,535
71,528
49,516
37,493
92,901
74,893
58,886
48,636
55,731
48,357
40,069
31,202
26,431
17,272
11,505
88,735
88,73511,50517,27226,43131,20240,06948,35755,73148,63658,88674,89392,90137,49349,51671,52869,53568,50887,002102,177115,631130,377146,884158,189165,702-57,034-47,96100-29,441
   Common Stock
1
0
0
1
1
3
3
3
3
3
3
3
3
6
17
17
4
5
5
5
5
6
6
6
1,470
0
0
0
1
10001,47066655554171763333333311001
   Retained Earnings -691,336-685,148-678,564-668,506-662,735-652,790-643,331-634,855-639,525-627,955-606,670-586,746-566,196-543,015-518,301-350,861-184,339-162,841-145,986-129,509-110,636-93,042-80,194-71,848-59,191-49,91500-30,115
   Accumulated Other Comprehensive Income 
-26
0
0
-15
-51
-202
-150
-101
-96
-10
5
35
24
-40
0
0
0
0
0
0
0
0
0
0
-211
0
0
0
26
26000-2110000000000-4024355-10-96-101-150-202-51-1500-26
   Capital Surplus 00000000000000000000000000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
699
0
0
1,968
2,207
237,749
71,614
85,066
241,106
245,147
248,155
249,805
68,481
420,430
589,812
592,514
603,685
679,642
681,558
686,836
688,156
690,580
691,682
692,853
692,467
694,937
695,836
696,653
780,044
780,044696,653695,836694,937692,467692,853691,682690,580688,156686,836681,558679,642603,685592,514589,812420,43068,481249,805248,155245,147241,10685,06671,614237,7492,2071,96800699



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue424
Cost of Revenue-0
Gross Profit424424
 
Operating Income (+$)
Gross Profit424
Operating Expense-29,682
Operating Income-29,258-29,258
 
Operating Expense (+$)
Research Development16,307
Selling General Administrative13,375
Selling And Marketing Expenses0
Operating Expense29,68229,682
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-29,258
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-27,872-30,644
EBIT - interestExpense = 0
-27,872
-28,452
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-27,872
Earnings Before Interest and Taxes (EBITDA)-29,258
 
After tax Income (+$)
Income Before Tax-27,872
Tax Provision-13
Net Income From Continuing Ops-29,481-27,885
Net Income-28,452
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses29,682
Total Other Income/Expenses Net1,3860
 

Technical Analysis of Vyne Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Vyne Therapeutics Inc. The general trend of Vyne Therapeutics Inc is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Vyne Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Vyne Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.17 < 4.16 < 4.293.

The bearish price targets are: 1.9 > 1.67.

Tweet this
Vyne Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Vyne Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Vyne Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Vyne Therapeutics Inc. The current macd is 0.0274959.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Vyne Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Vyne Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Vyne Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Vyne Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartVyne Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Vyne Therapeutics Inc. The current adx is 23.03.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Vyne Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Vyne Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Vyne Therapeutics Inc. The current sar is 3.00353974.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Vyne Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Vyne Therapeutics Inc. The current rsi is 40.92. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Vyne Therapeutics Inc Daily Relative Strength Index (RSI) ChartVyne Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Vyne Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Vyne Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Vyne Therapeutics Inc Daily Stochastic Oscillator ChartVyne Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Vyne Therapeutics Inc. The current cci is -127.71706345.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Vyne Therapeutics Inc Daily Commodity Channel Index (CCI) ChartVyne Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Vyne Therapeutics Inc. The current cmo is -31.61013097.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Vyne Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartVyne Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Vyne Therapeutics Inc. The current willr is -94.56521739.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Vyne Therapeutics Inc Daily Williams %R ChartVyne Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Vyne Therapeutics Inc.

Vyne Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Vyne Therapeutics Inc. The current atr is 0.23521867.

Vyne Therapeutics Inc Daily Average True Range (ATR) ChartVyne Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Vyne Therapeutics Inc. The current obv is 61,590,383.

Vyne Therapeutics Inc Daily On-Balance Volume (OBV) ChartVyne Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Vyne Therapeutics Inc. The current mfi is 30.31.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Vyne Therapeutics Inc Daily Money Flow Index (MFI) ChartVyne Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Vyne Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-11ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Vyne Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Vyne Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.916
Ma 20Greater thanMa 502.730
Ma 50Greater thanMa 1002.399
Ma 100Greater thanMa 2002.450
OpenGreater thanClose2.390
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Vyne Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Vyne Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Vyne Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Vyne Therapeutics Inc

I send you an email if I find something interesting about Vyne Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Vyne Therapeutics Inc.

Receive notifications about Vyne Therapeutics Inc in your mailbox!